Competencies by role
Physician
The medical doctor responsible for physical safety, eligibility, and monitoring before, during, and after dosing.
99 competencies mapped for this role.
Assess yourself against this role's competencies →
Looking for something specific? Ask Blossom
Screening, eligibility, and readiness assessment
Teaches how to assess clinical suitability before psychedelic or ketamine treatment, including medical and psychiatric screening, readiness evaluation, contraindication review, inclusion/exclusion criteria, and ongoing eligibility re-checks before dosing.
8 care stages · 52 guidelines · 15 courses · 12 providers
5-MeO-DMTDMT / AyahuascaIbogaine+4 moreAcute psychological response and emergency management during dosing
Cluster covering 35 related competencies for monitoring acute psychological effects, recognising and managing distress, crisis containment, emergency escalation, and rescue-medication coordination during psychedelic dosing sessions.
8 care stages · 51 guidelines · 2 courses · 2 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreAdverse event identification, documentation, and reporting
Teaches how to detect, elicit, document, and report adverse events and serious adverse events across the participant journey. The focus is accurate source documentation, regulatory reporting discipline, follow-up, and preservation of participant safety and trial integrity.
7 care stages · 46 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 morePreparation and integration support
Cluster covering 31 related competencies including: Integration support, Integration therapy, Integration coaching.
8 care stages · 43 guidelines · 18 courses · 14 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreSuicide and serious psychiatric risk assessment
Teaches structured assessment of suicidal ideation, intent, psychiatric deterioration, and related high-risk presentations. Learners are trained to use appropriate tools, safety planning, emergency contacts, clinician access, and escalation pathways when risk is identified.
7 care stages · 41 guidelines · 1 courses · 1 providers
5-MeO-DMTDMT / AyahuascaKetamine+3 moreManual fidelity, protocol adherence, and deviation management
Teaches faithful delivery of manualized treatment and protocol-defined procedures while documenting and managing unavoidable deviations. The competency protects participant welfare, treatment consistency, data integrity, and sponsor oversight.
7 care stages · 39 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaKetamine+4 morePost-dose follow-up, safety monitoring, and retention support
Teaches ongoing participant contact after dosing to support stability, detect delayed adverse effects, maintain therapeutic containment, and sustain adherence to follow-up visits and outcome assessments.
7 care stages · 37 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+4 moreDischarge readiness, escort safety, and post-session supervision
Teaches how to determine when a participant is safe to leave after dosing and how to arrange appropriate supervision afterward. The competency covers psychological and physical stability, escort/support-person coordination, discharge restrictions, overnight or post-session support, and follow-up contact when needed.
8 care stages · 30 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaKetamine+3 moreEmergency recognition, escalation, and disposition planning
Teaches recognition of medical or psychiatric emergencies and the steps required to escalate care safely. The competency includes de-escalation, clinical consultation, 911 or emergency department transfer, serious-event escalation, and referral to appropriate higher-level care.
7 care stages · 29 guidelines · 3 courses · 3 providers
5-MeO-DMTDMT / AyahuascaIbogaine+4 moreBlinding, allocation concealment, and unblinding control
Teaches how to preserve blinded trial conduct across participant interactions, outcome collection, staff roles, and session procedures. The competency includes preventing accidental unblinding, minimizing bias, and using emergency unblinding only when clinically necessary.
8 care stages · 29 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaKetamine+4 moreMedication, substance-use, washout, and taper management
Teaches review and management of concomitant medications, restricted therapies, prohibited substances, washout periods, tapering requirements, and abstinence expectations. The competency includes participant counseling, medication reconciliation, sponsor notification, and team coordination when restrictions affect safety or interpretability.
7 care stages · 29 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaKetamine+3 moreTherapeutic boundaries, professional conduct, and consent for touch
Teaches how to maintain clear relational and physical boundaries in emotionally vulnerable treatment settings. This includes professional conduct, rapport without overreach, explicit consent for touch, the right to revoke consent, and strict prohibition of sexual or erotic contact.
8 care stages · 24 guidelines · 4 courses · 3 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreCo-therapist and multidisciplinary team coordination
Teaches coordinated practice across co-therapists, physicians, psychiatrists, study coordinators, principal investigators, and other care-team members. The focus is shared responsibility, clear communication, role clarity, and coordinated observation of participant status.
8 care stages · 24 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+4 morePhysical safety monitoring
Cluster covering 3 related competencies including: Physical safety monitoring, Safety monitoring during dosing sessions, Medical safety monitoring during psilocybin administration.
6 care stages · 19 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+2 moreAcute psychiatric and behavioral risk monitoring
Teaches continuous monitoring for distress, confusion, psychotic symptoms, suicidality, agitation, and other acute behavioral risks during and after dosing. The focus is early recognition, documentation, and escalation to clinical support when risk emerges.
7 care stages · 17 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaKetamine+3 moreEthical conduct in human-subject research
Able to practice ethically in a clinical trial environment involving a Schedule-sensitive psychoactive intervention. This includes protecting participants, adhering to protocol, and supporting valid informed participation.
7 care stages · 16 guidelines · 0 courses · 0 providers
DMT / AyahuascaIbogaineLSD+3 morePsilocybin session facilitation
Cluster covering 9 related competencies including: Psilocybin facilitation, Psilocybin session support, Psilocybin facilitation basics.
8 care stages · 14 guidelines · 6 courses · 5 providers
LSDPsilocybinAdverse effects and side-effect management
Teaches recognition and management of expected and unexpected side effects during psychedelic or ketamine treatment. The competency emphasizes active observation, supportive response, and clinical escalation when symptoms exceed routine tolerability.
6 care stages · 14 guidelines · 1 courses · 1 providers
DMT / AyahuascaIbogaineKetamine+3 morePsychedelic-assisted psychotherapy preparation and integration
Teaches structured pre-dose preparation and post-dose integration as the therapeutic frame for psychedelic-assisted psychotherapy. The therapist supports rapport, intention clarification, meaning-making, emotional processing, and consolidation of insights after dosing.
8 care stages · 13 guidelines · 2 courses · 2 providers
5-MeO-DMTDMT / AyahuascaKetamine+3 moreHallucinogen pharmacology and effects
Cluster covering 7 related competencies including: Physiologic safety awareness, Hallucinogen pharmacology and effects, Hallucinogen-assisted therapy knowledge.
6 care stages · 13 guidelines · 0 courses · 0 providers
LSDPsilocybinKetamine psychotherapy delivery
Cluster covering 12 related competencies including: KAP psychotherapy delivery, Ketamine and KAP knowledge, Ketamine integration planning.
8 care stages · 12 guidelines · 7 courses · 5 providers
KetamineDissociation and acute neuropsychiatric effect monitoring
Teaches recognition and documentation of dissociation, psychosis-like symptoms, mania, and other acute neuropsychiatric effects that can occur after ketamine, psychedelic dosing, or related interventions. The focus is monitoring, reporting, and escalation when symptoms become clinically significant.
7 care stages · 12 guidelines · 0 courses · 0 providers
DMT / AyahuascaIbogaineKetamine+1 morePhysiologic monitoring, thermoregulation, hydration, and overdose response
Teaches monitoring and response for acute physiological risks, including vital signs, temperature, hydration, overheating, excessive fluid intake, and suspected overdose. The competency emphasizes supportive care, medical coordination, documentation, and escalation when needed.
5 care stages · 11 guidelines · 0 courses · 0 providers
DMT / AyahuascaKetamineMDMA+1 moreSpecial-interest adverse event vigilance
The protocol requires active monitoring for psychedelic-specific adverse events such as hallucinations, psychotic symptoms, dissociation, mood alteration, and cognitive disturbance. These require immediate notification and follow-up.
7 care stages · 11 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+3 moreMindfulness, intention-setting, set and setting, and somatic presence
Teaches practices that support preparation and therapeutic presence, including mindfulness, intention-setting, body-aware attention, environmental preparation, mindset awareness, and regulation through somatic presence.
7 care stages · 9 guidelines · 7 courses · 6 providers
5-MeO-DMTDMT / AyahuascaIbogaine+4 moreComprehensive psychiatric assessment
Ability to perform or supervise detailed psychiatric evaluation for diagnosis, eligibility, and ongoing monitoring. The therapist/facilitator must understand symptom presentations relevant to MDD, AUD, suicidality, psychosis, and dissociation.
4 care stages · 9 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+2 moreContinuation, discontinuation, and risk-benefit judgment
Teaches how clinicians determine whether a participant should proceed, pause, discontinue dosing, or terminate study participation. The competency centers on safety-driven clinical judgment, risk-benefit assessment, and early termination when continuation is no longer appropriate.
6 care stages · 8 guidelines · 0 courses · 0 providers
KetamineMDMAPsilocybinPhysiologic monitoring during ketamine administration
Cluster covering 2 related competencies including: Safety monitoring during ketamine dosing, Physiologic monitoring during ketamine administration.
6 care stages · 8 guidelines · 0 courses · 0 providers
KetamineVital sign and physical distress monitoring
Monitors participant physical status during study visits and identifies concerning changes requiring escalation. Vital signs and symptomatic changes are part of routine safety observation.
6 care stages · 8 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+1 moreCultural humility, Indigenous respect, and equity-oriented care
Teaches culturally responsive psychedelic care, including humility, anti-bias practice, Indigenous and traditional-use awareness, cultural appropriation concerns, diversity and inclusion, and respectful work with marginalized communities.
8 care stages · 7 guidelines · 11 courses · 10 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreMedical escalation and rescue medication coordination
Cluster covering 2 related competencies including: Medical escalation and rescue medication use, Medical escalation and rescue medication coordination.
4 care stages · 7 guidelines · 0 courses · 0 providers
5-MeO-DMTPsilocybinParticipant-centered discharge planning and aftercare
Support decision-making about ongoing treatment after trial completion, particularly for participants who received escitalopram. The clinician helps participants consider whether to continue, taper, or return to usual care.
5 care stages · 7 guidelines · 0 courses · 0 providers
IbogaineKetamineMDMA+1 moreMedication taper and withdrawal monitoring
Teaches monitoring during down-titration or discontinuation of psychiatric medications before dosing. Learners track withdrawal symptoms, symptom worsening, suicidality, and other risks that may emerge during tapering.
4 care stages · 6 guidelines · 0 courses · 0 providers
IbogainePsilocybinPsilocybin psychotherapy framework
Cluster covering 4 related competencies including: Psychedelic therapy workflow, Psilocybin psychotherapy framework, Psilocybin-assisted psychotherapy framework.
8 care stages · 5 guidelines · 4 courses · 2 providers
DMT / AyahuascaKetaminePsilocybinEthical psychedelic facilitation
Cluster covering 3 related competencies including: Ethical psychedelic facilitation, Safe, legal psychedelic care facilitation, Ethical decision-making in psychedelic facilitation.
8 care stages · 5 guidelines · 2 courses · 2 providers
5-MeO-DMTIbogaineKetamine+1 moreManagement of concomitant medication interactions
Cluster covering 5 related competencies including: Concomitant medication review, Contraindication and interaction awareness, Contraindications, drug effects, and interactions.
5 care stages · 5 guidelines · 1 courses · 1 providers
IbogaineLSDPsilocybinProvide overnight and next-day containment
Therapists must ensure continuity of care after the acute session, including overnight observation and next-morning integration before discharge. This reflects a containment and recovery responsibility beyond the dosing period.
5 care stages · 5 guidelines · 0 courses · 0 providers
DMT / AyahuascaIbogaineLSD+2 moreRisk screening and exclusion judgment
Know the medical and psychiatric exclusions that protect participants from foreseeable harm. Facilitators must recognize conditions that make MDMA-assisted psychotherapy unsafe or inappropriate.
4 care stages · 5 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+2 moreProfessional self-care and burnout prevention
Teaches sustainable self-care practices for clinicians and facilitators working in emotionally intense settings. The competency supports emotional resilience, ethical boundaries, reflective practice, and burnout prevention.
6 care stages · 4 guidelines · 3 courses · 3 providers
KetamineMDMAPsilocybinRisk evaluation and safety monitoring
Teaches continuous evaluation of clinical risk and maintenance of a safe care environment throughout preparation, dosing, and follow-up. Learners monitor risk signals, apply safety procedures, and escalate care when needed.
8 care stages · 4 guidelines · 3 courses · 2 providers
5-MeO-DMTIbogaineKetamine+2 moreManage agitation and elopement risk
Respond to agitation or attempts to leave the room in a way that preserves safety for the patient and others. The therapist should use containment, redirection, and escalation protocols when needed.
4 care stages · 4 guidelines · 0 courses · 0 providers
5-MeO-DMTLSDMDMA+1 morePrioritize participant wellbeing over research aims
Participant safety and wellbeing must take precedence over scientific objectives at all times. Therapists must communicate and operationalize this priority throughout screening, treatment, and follow-up.
4 care stages · 4 guidelines · 0 courses · 0 providers
DMT / AyahuascaMDMACrisis and adverse-event response
The page signals training in managing difficult or high-risk moments, including crisis intervention and trigger management. Learners are expected to respond appropriately when a session becomes destabilizing or unsafe.
6 care stages · 3 guidelines · 1 courses · 1 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreKnowledge of MDMA effects and risks
Facilitators must understand the expected psychological, physiological, and potential adverse effects of MDMA in order to prepare participants, support the session, and detect complications.
5 care stages · 3 guidelines · 0 courses · 0 providers
MDMAMRI safety screening and imaging-session coordination
Teaches screening for MRI contraindications and coordination of imaging clearance before scan procedures. The competency prevents exposure of ineligible participants to magnetic-resonance risks and supports safe imaging-session logistics.
3 care stages · 3 guidelines · 0 courses · 0 providers
MDMAPsilocybinPre-treatment clinical risk assessment
Understand the major medical risks associated with ibogaine administration, especially cardiac and neurologic toxicity, before proceeding with treatment. This includes recognizing that ibogaine has been linked to torsades de pointes, QTc prolongation, bradycardia, and ataxia.
4 care stages · 3 guidelines · 0 courses · 0 providers
IbogaineProfessional qualifications and experience threshold
The manual specifies baseline professional requirements for study therapists. These include licensure and substantial clinical experience with psychiatric populations.
3 care stages · 3 guidelines · 0 courses · 0 providers
MDMAPsilocybinResearch rating fidelity
Ability to administer standardized clinical ratings consistently and under supervision. Reliable measurement is essential for efficacy and safety endpoints.
4 care stages · 3 guidelines · 0 courses · 0 providers
5-MeO-DMTIbogaineKetamineHarm reduction and risk awareness
Cluster covering 5 related competencies including: Harm-reduction orientation, Harm reduction and risk awareness, Harm reduction for client support.
8 care stages · 2 guidelines · 5 courses · 5 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreLegal and Regulatory Navigation
Teaches practitioners to identify and apply relevant legal, regulatory, ethical, and institutional requirements, including documentation, consent, reporting, controlled-substance, and jurisdiction-specific obligations.
7 care stages · 2 guidelines · 2 courses · 2 providers
IbogaineKetamineMDMA+1 moreBasic life support
Learners are explicitly offered Basic Life Support training, indicating emergency readiness and medical safety preparation. The page notes DORA-required status, signaling regulatory safety relevance.
4 care stages · 2 guidelines · 1 courses · 1 providers
5-MeO-DMTKetamineAssessment of emotional stability after sessions
Therapists must remain with participants at the end of and immediately after experimental sessions until emotional stability is established. This requires real-time clinical judgment about readiness for reduced supervision.
3 care stages · 2 guidelines · 0 courses · 0 providers
DMT / AyahuascaMDMACoordinate with outside providers ethically
Therapists must coordinate with prescribing clinicians and existing psychotherapists when relevant, while respecting consent and confidentiality. Communication should support safety, continuity, and protocol integrity.
3 care stages · 2 guidelines · 0 courses · 0 providers
MDMANighttime and overnight participant support
When overnight stays are required, facilitators and attendants must maintain safe observation and supportive presence without acting as outside therapists. They need to monitor comfort, safety, and emergency access overnight.
4 care stages · 2 guidelines · 0 courses · 0 providers
MDMAProfessional qualification and supervised practice
Lead therapists must hold appropriate licensure and regulatory registration to provide psychotherapy, and have prior PAP experience. Unlicensed or inexperienced therapists may participate only under direct supervision.
2 care stages · 2 guidelines · 0 courses · 0 providers
KetaminePsilocybinProtection against coercion and dual-role influence
The protocol explicitly addresses the risk of undue influence when investigators recruit current or former patients, requiring safeguards and ongoing monitoring for coercion.
3 care stages · 2 guidelines · 0 courses · 0 providers
MDMAShared decision-making and referral coordination
Collaborates with patients, medical practitioners, and referring providers to support individualized care. Helps patients consider alternatives and coordinate ongoing treatment needs.
4 care stages · 2 guidelines · 0 courses · 0 providers
IbogaineKetamineWork within medically supervised settings
LSD-assisted psychotherapy in this study is explicitly framed as medically supervised. Therapists/facilitators need to practice within a setting capable of medical oversight and management of prolonged altered states.
2 care stages · 2 guidelines · 0 courses · 0 providers
IbogaineLSDPsychedelic research literacy and evidence appraisal
Teaches how to interpret the psychedelic clinical evidence base, compare strength of evidence across indications, understand mechanism theories, and critically appraise research claims. The competency supports evidence-informed practice rather than relying on general field narratives.
7 care stages · 1 guidelines · 11 courses · 8 providers
IbogaineKetamineLSD+2 moreProfessional Scope and Practice Alignment
Teaches clinicians to recognise their role boundaries, align services with training, licensure, supervision, and organisational policy, and refer or escalate when participant needs fall outside their scope of competence.
5 care stages · 1 guidelines · 3 courses · 2 providers
IbogaineMDMAPsilocybinPharmacology, contraindications, and interaction awareness
Teaches psychoactive substance pharmacology, expected drug effects, contraindications, and relevant drug-interaction risks. The competency supports safer screening, medication review, participant education, and clinical decision-making.
4 care stages · 1 guidelines · 2 courses · 2 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreAppropriate facilitator qualifications
Lead facilitators were doctoral-level psychologists or physicians with major depressive disorder treatment experience, and co-facilitators had at least a bachelor’s degree in a mental health-related field. The source therefore indicates role-appropriate clinical background and experience requirements.
2 care stages · 1 guidelines · 0 courses · 0 providers
PsilocybinBenzodiazepine-support management
Use supportive anxiolytic or hypnotic medication only when allowed and clinically indicated. This requires careful judgment to balance comfort, safety, and preservation of the session’s integrity.
3 care stages · 1 guidelines · 0 courses · 0 providers
DMT / AyahuascaClinician therapist availability and scope
At least one therapist in the dyad must be a clinician with capability to assess and manage medical or psychiatric adverse events during the dosing session. This reflects a required competency boundary between general support and clinical responsibility.
3 care stages · 1 guidelines · 0 courses · 0 providers
PsilocybinCompetence in specialized psychedelic therapy training
The protocol implies that facilitators should have specific psychiatric, psychotherapeutic, or psycholytic therapy training relevant to altered-state treatment. Specialized experience supports safe and effective delivery of LSD-assisted psychotherapy.
1 care stage · 1 guidelines · 0 courses · 0 providers
LSDDeterioration triage and referral
Ability to judge clinical worsening over time and determine whether a participant can remain in the study or requires higher-level care. This is a continuing monitoring responsibility throughout the trial.
1 care stage · 1 guidelines · 0 courses · 0 providers
KetamineDyadic facilitation and gender-balanced therapeutic presence
Experimental sessions are conducted by a male physician-investigator and an experienced female nurse, indicating competency in co-therapy, complementary roles, and continuous therapeutic presence.
1 care stage · 1 guidelines · 0 courses · 0 providers
MDMAEvaluate readiness and contraindications for subsequent sessions
After each MDMA session, therapists must assess whether continuing treatment is safe and clinically appropriate. The participant’s choice is respected unless safety concerns warrant exclusion.
2 care stages · 1 guidelines · 0 courses · 0 providers
MDMAIbogaine-specific cardiac vigilance
Understand the unique cardiovascular hazards associated with ibogaine and the need for intensive cardiac oversight. The facilitator should know that cardiac risk is a central safety issue rather than a minor side effect.
2 care stages · 1 guidelines · 0 courses · 0 providers
IbogaineDMT / AyahuascaInterprofessional coordination and referral management
Safe delivery requires coordination among therapists, physicians, nurses, blinded assessors, outside therapists, and emergency services.
3 care stages · 1 guidelines · 0 courses · 0 providers
MDMAManagement of dual relationships and undue influence
Therapists must protect voluntariness when potential participants are also their patients. Independent evaluation should be used to reduce pressure or perceived coercion in recruitment and consent.
3 care stages · 1 guidelines · 0 courses · 0 providers
MDMAOn-site physician emergency competence
A study physician with psychiatric and cardiovascular emergency expertise must be available during dosing. This reflects a requirement for advanced emergency readiness and clinical judgment.
3 care stages · 1 guidelines · 0 courses · 0 providers
KetamineOverdose, misuse, and abuse-liability vigilance
Facilitators are expected to monitor for signs of misuse, diversion, dependence, or other abuse-related phenomena even though the medication is administered only on-site. They must also recognize protocol violations or dropout patterns that may signal abuse liability concerns.
3 care stages · 1 guidelines · 0 courses · 0 providers
MDMAParticipant preparation for medication adherence
Prepare participants to correctly use nicotine replacement therapy when assigned to the control arm. Facilitators must provide education, dosing instructions, and side-effect guidance.
2 care stages · 1 guidelines · 0 courses · 0 providers
PsilocybinQualified psychiatric interview
Conducts a retrospective psychiatric interview to judge minimal clinical improvement on the current antidepressant regimen. Uses multiple information sources and clinical observation to determine whether the participant meets screening requirements.
1 care stage · 1 guidelines · 0 courses · 0 providers
KetamineSafety escalation and collaboration
Knows when to involve physicians, psychologists, and independent safety oversight. Complex psychedelic sessions require clear escalation pathways and team coordination.
3 care stages · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTStructured psychiatric screening collaboration
Understands the screening instruments and the respective roles of site staff and independent raters. The facilitator must collaborate with rater findings while maintaining appropriate boundaries and blinding.
1 care stage · 1 guidelines · 0 courses · 0 providers
MDMATraining and supervision compliance
Operate only within the bounds of formal training, supervision, and site authorization. The protocol expects specialized training for facilitators, raters, and all staff interacting with participants or data.
1 care stage · 1 guidelines · 0 courses · 0 providers
PsilocybinCase-based practice, peer consultation, and professional learning community
Teaches applied competence through role play, case discussion, peer consultation, seminars, mentorship, and learning-community structures. The emphasis is translating theory into practice, receiving feedback, and developing reflective clinical judgment with peers.
8 care stages · 0 guidelines · 8 courses · 7 providers
KetaminePsilocybinPsychedelic therapy foundation
Cluster covering 7 related competencies including: Psychedelic therapy foundation, Psychedelic therapy foundations, Psychedelic practice fundamentals.
4 care stages · 0 guidelines · 6 courses · 5 providers
KetamineMDMAPsilocybinEthics and ethical practice
Cluster covering 4 related competencies including: Ethical practice, Ethics in psychedelic care, Ethics and ethical practice.
8 care stages · 0 guidelines · 4 courses · 3 providers
MDMAPsilocybinClinical protocol literacy
Teaches practitioners to read and understand clinical protocols, treatment manuals, and evidence-based psychedelic care procedures. The focus is knowing how protocol requirements shape preparation, dosing, integration, documentation, and safety responsibilities.
5 care stages · 0 guidelines · 2 courses · 2 providers
KetamineMDMAPsilocybinProfessional application and practice development
Teaches practitioners how to translate psychedelic-informed training into professional practice, including applied skill development, scope awareness, practice-building considerations, and integration of competencies into real clinical or wellness settings.
4 care stages · 0 guidelines · 2 courses · 2 providers
Complex-case support and ethics-based clinical judgment
Teaches work with clinically complex contexts such as trauma, palliative care, and other nuanced presentations where ethical judgment, scope discipline, careful assessment, and individualized support are required.
3 care stages · 0 guidelines · 2 courses · 1 providers
PsilocybinLegal access pathways and care-team coordination
Teaches how participants move through lawful access routes and coordinated care pathways. The competency covers referral navigation, team handoffs, and the practical steps needed to connect eligible participants with appropriate treatment or study settings.
5 care stages · 0 guidelines · 2 courses · 1 providers
MDMAPsilocybinPsilocybin prescribing fundamentals
Cluster covering 2 related competencies including: Psilocybin prescribing fundamentals, Prescribing fundamentals for psychedelic treatment.
6 care stages · 0 guidelines · 2 courses · 1 providers
MDMAPsilocybinClinical collaboration and compliance awareness
The page repeatedly emphasizes integrity, compliance, and collaboration with professional organizations and researchers. Learners are expected to practice within evolving regulatory and clinical standards.
1 care stage · 0 guidelines · 1 courses · 1 providers
Clinical trial training and feedback use
The page highlights best-in-class clinical training for drug trials and AI-supported evaluation. Learners are expected to refine skills quickly and receive targeted feedback in training or evaluation contexts.
8 care stages · 0 guidelines · 1 courses · 1 providers
Collaborative-care role awareness
The program emphasizes that it prepares people for therapeutic and facilitative roles within a collaborative care framework, not independent medical practice. Learners are expected to understand role boundaries, especially around prescribing and administration.
5 care stages · 0 guidelines · 1 courses · 1 providers
KetaminePsilocybinCompound comparison for therapeutic use
The course teaches learners to distinguish between classic psychedelics and emerging therapies within therapeutic applications. This is a foundational comparative literacy competency rather than a protocol-specific skill.
6 care stages · 0 guidelines · 1 courses · 1 providers
KetamineLSDMDMA+1 moreContraindication and interaction review
The page explicitly notes medication interactions, contraindications, and risk management for prescribers. This indicates training in identifying unsafe combinations and excluding or delaying treatment when needed.
3 care stages · 0 guidelines · 1 courses · 1 providers
MDMAPsilocybinEthical decision-making and confidentiality
The practicum explicitly says sites cover ethical considerations such as confidentiality, privacy, professional conduct, and ethical decision-making. Ethical alignment is also part of site approval.
2 care stages · 0 guidelines · 1 courses · 1 providers
Ethical grounding and integrity
The course repeatedly emphasizes ethical considerations, safety, and integrity in practice. Learners are expected to develop a grounded professional stance that respects legal boundaries and participant welfare.
3 care stages · 0 guidelines · 1 courses · 1 providers
Referral and further-training planning
The workshop provides recommendations for obtaining further training, signaling a competency in identifying next-step education and appropriate escalation pathways. This supports responsible scope-of-practice decisions.
1 care stage · 0 guidelines · 1 courses · 1 providers
Safety and legal boundaries awareness
The page includes explicit warnings about what graduates can and cannot legally do. Learners are expected to understand scope limits, licensure requirements, and when consultation supervision is needed.
3 care stages · 0 guidelines · 1 courses · 1 providers
KetamineMDMAPsilocybinSafety-oriented documentation and templates
Trainees receive templates such as consent and intake forms, informational documents, and guidelines, which implies competence in using standardized practice materials. The page also signals procedural support for safe and organized care delivery.
5 care stages · 0 guidelines · 1 courses · 1 providers
KetamineSustainable practice development and prescriber coordination
The course teaches practical steps to launch and sustain a KAP practice, including forging relationships with prescribers and identifying suitable practicum sites. This is framed as part of professional development and business planning.
3 care stages · 0 guidelines · 1 courses · 1 providers
KetamineUse structured preparedness frameworks
The course is positioned as a preparedness-oriented training with self-directed preparation plus live facilitated learning. Learners are expected to internalize a framework for managing challenging or crisis moments with confidence and care.
2 care stages · 0 guidelines · 1 courses · 1 providers
General psychedelic-assisted practice skills
Catch-all cluster covering 189 general competencies for psychedelic-assisted clinical practice that did not group into a more specific category — including miscellaneous facilitation, monitoring, ethics, safety, regulatory awareness, group support, and program-specific skills not captured by dedicated clusters elsewhere.
8 care stages · 45 guidelines · 27 courses · 18 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 more
Other roles
Explore the competencies each team role carries.